Bisphosphonates in the prevention of disease recurrence: Current results and ongoing trials

Current Cancer Drug Targets

Volumn 9, Issue 7, 2009, Pages 824-833

  Gnant, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bisphosphonates; Breast cancer; Disease recurrence; Lung cancer; Multiple myeloma; Prostate cancer; Survival; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PLACEBO; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; HUMAN; HYPERCALCEMIA; LUNG CANCER; MULTIPLE MYELOMA; OSTEOLYSIS; PROSTATE CANCER; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SOLID TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HUMANS; NEOPLASM METASTASIS; TREATMENT OUTCOME;

EID: 72849140888     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800909789760267     Document Type: Review

References (47)

1. Major, P. Optimal management of metastatic bone disease. Eur. J. Oncol. Nurs. 2007, 11(Suppl. 2), S32-S37.
2. Wardley, A.; Davidson, N.; Barrett-Lee, P.; Hong, A.; Mansi, J.; Dodwell, D.; Murphy, R.; Mason, T.; Cameron, D. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. Br. J. Cancer 2005, 92, 1869-1876. (Pubitemid 40826135)
3. Kretzschmar, A.; Wiege, T.; Al-Batran, S. E.; Hinrichs, H. F.; Kindler, M.; Steck, T.; Illiger, H. J.; Heinemann, V.; Schmidt, K.; Haus, U.; Kirner, A.; Ehninger, G. Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: a multicenter open-label study over 1 year. Support. Cancer Ther. 2007, 4, 203-210.
4. Lipton, A.; Zheng, M.; Seaman, J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003, 98, 962-969. (Pubitemid 37022096)
5. Rosen, L. S.; Gordon, D.; Kaminski, M.; Howell, A.; Belch, A.; Mackey, J.; Apffelstaedt, J.; Hussein, M. A.; Coleman, R. E.; Reitsma, D. J.; Chen, B.-L.; Seaman, J. J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, doubleblind, multicenter, comparative trial. Cancer 2003, 98, 1735-1744.
6. Rosen, L. S.; Gordon, D.; Tchekmedyian, N. S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100, 2613-2621. (Pubitemid 38715767)
7. Saad, F.; Gleason, D. M.; Murray, R.; Tchekmedyian, S.; Venner, P.; Lacombe, L.; Chin, J. L.; Vinholes, J. J.; Goas, J. A.; Zheng, M. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004, 96, 879-882. (Pubitemid 38807610)
8. Lipton, A.; Cook, R.; Saad, F.; Major, P.; Garnero, P.; Terpos, E.; Brown, J. E.; Coleman, R. E. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113, 193-201.
9. Berenson, J. R.; Lichtenstein, A.; Porter, L.; Dimopoulos, M. A.; Bordoni, R.; George, S.; Lipton, A.; Keller, A.; Ballester, O.; Kovacs, M.; Blacklock, H.; Bell, R.; Simeone, J. F.; Reitsma, D. J.; Heffernan, M.; Seaman, J.; Knight, R. D. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J. Clin. Oncol. 1998, 16, 593-602.
10. Saad, F. New research findings on zoledronic acid: survival, pain, and anti-tumour effects. Cancer Treat. Rev. 2008, 34, 183-192.
11. Coleman, R. E.; Major, P.; Lipton, A.; Brown, J. E.; Lee, K. A.; Smith, M.; Saad, F.; Zheng, M.; Hei, Y. J.; Seaman, J.; Cook, R. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 2005, 23, 4925-4935. (Pubitemid 46223998)
12. Hirsh, V.; Major, P. P.; Lipton, A.; Cook, R. J.; Langer, C. J.; Smith, M. R.; Brown, J. E.; Coleman, R. E. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J. Thorac. Oncol. 2008, 3, 228-236.
13. Lipton, A.; Cook, R. J.; Major, P.; Smith, M. R.; Coleman, R. E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12, 1035-1043. (Pubitemid 350007015)
14. Winter, M. C.; Holen, I.; Coleman, R. E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev. 2008, 34, 453-475.
15. Benassi, M. S.; Chiechi, A.; Ponticelli, F.; Pazzaglia, L.; Gamberi, G.; Zanella, L.; Manara, M. C.; Perego, P.; Ferrari, S.; Picci, P. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 2007, 250, 194-205. (Pubitemid 46529443)
16. Budman, D. R.; Calabro, A. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology 2006, 70, 147-153. (Pubitemid 43760341)
17. Duivenvoorden, W. C.; Vukmirovic-Popovic, S.; Kalina, M.; Seidlitz, E.; Singh, G. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br. J. Cancer 2007, 96, 1526-1531. (Pubitemid 46762946)
18. Ottewell, P. D.; Deux, B.; Monkkonen, H.; Cross, S.; Coleman, R. E.; Clezardin, P.; Holen, I. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin. Cancer Res. 2008, 14, 4658-4666.
19. Ottewell, P. D.; Monkkonen, H.; Jones, M.; Lefley, D. V.; Coleman, R. E.; Holen, I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J. Natl. Cancer Inst. 2008, 100, 1167-1178.
20. Ozturk, O. H.; Bozcuk, H.; Burgucu, D.; Ekinci, D.; Ozdogan, M.; Akca, S.; Yildiz, M. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study. Cell Biol. Int. 2007, 31, 1069-1071. (Pubitemid 46819059)
21. Aviles, A.; Nambo, M. J.; Neri, N.; Castaneda, C.; Cleto, S.; Huerta-Guzman, J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med. Oncol. 2007, 24, 227-230. (Pubitemid 350135975)
22. Mystakidou, K.; Katsouda, E.; Parpa, E.; Kelekis, A.; Galanos, A.; Vlahos, L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med. Oncol. 2005, 22, 195-201.
23. Vincenzi, B.; Santini, D.; Dicuonzo, G.; Battistoni, F.; Gavasci, M.; La Cesa, A.; Grilli, C.; Virzi, V.; Gasparro, S.; Rocci, L.; Tonini, G. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interferon Cytokine Res. 2005, 25, 144-151. (Pubitemid 40354834)
24. Aapro, M. S. Long-term implications of bone loss in breast cancer. Breast 2004, 13(Suppl. 1), S29-S37. (Pubitemid 39654741)
25. Hadji, P.; Body, J. J.; Aapro, M. S.; Brufsky, A.; Coleman, R. E.; Guise, T.; Lipton, A.; Tubiana-Hulin, M. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann. Oncol. 2008, 19, 1407-1416.
26. Powles, T.; Paterson, A.; McCloskey, E.; Schein, P.; Scheffler, B.; Tidy, A.; Ashley, S.; Smith, I.; Ottestad, L.; Kanis, J. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res. 2006, 8, R13. (Pubitemid 44376864)
27. Diel, I. J.; Solomayer, E.-F.; Costa, S. D.; Gollan, C.; Goerner, R.; Wallwiener, D.; Kaufmann, M.; Bastert, G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N. Engl. J. Med. 1998, 339, 357-363. (Pubitemid 28363797)
28. Diel, I. J.; Jaschke, A.; Solomayer, E. F.; Gollan, C.; Bastert, G.; Sohn, C.; Schuetz, F. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow - a long-term follow-up. Ann. Oncol. 2008, 19, 2007-2011.
29. Saarto, T.; Blomqvist, C.; Virkkunen, P.; Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J. Clin. Oncol. 2001, 19, 10-17. (Pubitemid 32063474)
30. Saarto, T.; Vehmanen, L.; Virkkunen, P.; Blomqvist, C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta. Oncol. 2004, 43, 650-656. (Pubitemid 39563937)
31. Ha, T. C.; Li, H. Meta-analysis of clodronate and breast cancer survival. Br. J. Cancer 2007, 96, 1796-1801. (Pubitemid 46912011)
32. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Pöstlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrick, M.; Fitzal, F.; Stierer, M.; Rucklinger, E.; Greil, R. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 2009, 360, 679-691.
33. Jakesz, R.; Hausmaninger, H.; Kubista, E.; Gnant, M.; Menzel, C.; Bauernhofer, T.; Seifert, M.; Haider, K.; Mlineritsch, B.; Steindorfer, P.; Kwasny, W.; Fridrik, M.; Steger, G.; Wette, V.; Samonigg, H. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer - Austrian Breast and Colorectal Cancer Study Group Trial 5. J. Clin. Oncol. 2002, 20, 4621-4627. (Pubitemid 36025277)
34. Gnant, M. F.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Grampp, S.; Kaessmann, H.; Schmid, M.; Menzel, C.; Piswanger-Soelkner, J. C.; Galid, A.; Mittlboeck, M.; Hausmaninger, H.; Jakesz, R. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J. Clin. Oncol. 2007, 25, 820-828. (Pubitemid 350002882)
35. Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Kainberger, F.; Kassmann, H.; Piswanger-Solkner, J. C.; Seifert, M.; Ploner, F.; Menzel, C.; Dubsky, P.; Fitzal, F.; Bjelic-Radisic, V.; Steger, G.; Greil, R.; Marth, C.; Kubista, E.; Samonigg, H.; Wohlmuth, P.; Mittlbock, M.; Jakesz, R. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008, 9, 840-849.
36. Bria, E.; Nistico, C.; Cuppone, F.; Carlini, P.; Ciccarese, M.; Milella, M.; Natoli, G.; Terzoli, E.; Cognetti, F.; Giannarelli, D. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106, 2337-2344. (Pubitemid 43787656)
37. Brufsky, A.; Bundred, N.; Coleman, R.; Lambert-Falls, R.; Mena, R.; Hadji, P.; Jin, L.; Schenk, N.; Ericson, S.; Perez, E. A. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13, 503-514. (Pubitemid 351872868)
38. Brufsky, A. M.; Bosserman, L. D.; Caradonna, R. R.; Haley, B. B.; Jones, C. M.; Moore, H. C.; Jin, L.; Warsi, G. M.; Ericson, S. G.; Perez, E. A. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin. Breast Cancer 2009, 9, 77-85.
39. http://clinicaltrials.gov/ct2/show/NCT00072020.
40. http://clinicaltrials.gov/ct2/show/NCT00512993.
41. http://www.success-studie.de.
42. http://clinicaltrials.gov/ct2/show/NCT00009945.
43. http://clinicaltrials.gov/ct2/show/NCT00127205.
44. http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=1737.
45. http://clinicaltrials.gov/ct2/show/NCT00193856
46. http://www.controlled-trials.com/ISRCTN66626762/zeus.
47. http://clinicaltrials.gov/ct2/show/NCT00172042.